NCT06108050 - JZP898 Intravenous Infusion as Monotherapy and Combination With Pembrolizumab in Adults With Advanced/Metastatic Solid Tumors | Biotech Hunter

Enrollment

177

Participants

Timeline

Start Date

November 7, 2023

Primary Completion Date

November 30, 2027

Study Completion Date

May 31, 2028

Conditions

Advanced Solid TumorMetastatic Solid Tumor

Interventions

DRUG

JZP898

Investigational drug monotherapy

DRUG

Pembrolizumab

Anti-PD1 antibody

Trial Locations (10)

19107

RECRUITING

Sidney Kimmel Cancer Center at Thomas Jefferson University Hospital, Philadelphia

22031

RECRUITING

Virginia Cancer Specialists, Fairfax

27710

RECRUITING

Duke University Medical Center - Duke Cancer Institute, Durham

32827

RECRUITING

Florida Cancer Specialists, Orlando

37203

RECRUITING

SCRI Oncology Partners, Nashville

75246

RECRUITING

Texas Oncology - Baylor Charles A Sammons Cancer Center, Dallas

77030

RECRUITING

The University of Texas MD Anderson Cancer Center, Houston

80218

RECRUITING

Sarah Cannon Research Institute at HealthONE, Denver

92024

RECRUITING

California Cancer Associates for Research and Excellence, Encinitas

93270

RECRUITING

California Cancer Associates for Research and Excellence, Fresno